Thomas A. Macek, Ph.D.
Affiliations: | Emory University, Atlanta, GA |
Google:
"Thomas Macek"Mean distance: 15.13 (cluster 6)
Parents
Sign in to add mentor| Jeffrey P. Conn | grad student | 2000 | Emory | |
| (Modulation of mGluR7 function by protein kinase C.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Strauss KA, Farrar MA, Muntoni F, et al. (2022) Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nature Medicine |
| Strauss KA, Farrar MA, Muntoni F, et al. (2022) Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nature Medicine |
| Day JW, Finkel RS, Chiriboga CA, et al. (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. The Lancet. Neurology. 20: 284-293 |
| Macek TA, Suzuki K, Asin K, et al. (2020) Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor. The International Journal of Neuropsychopharmacology |
| Yurgelun-Todd DA, Renshaw PF, Goldsmith P, et al. (2019) A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects. Psychopharmacology |
| Day JW, Chiriboga CA, Crawford TO, et al. (2019) 066 Avxs-101 gene-replacement therapy (GRT) for spinal muscular atrophy type 1 (SMA1): pivotal phase 3 study (STR1VE) update Journal of Neurology, Neurosurgery & Psychiatry. 90: A22.1-A22 |
| Day JW, Chiriboga CA, Crawford TO, et al. (2019) 250 AVXS-101 phase 3 study in spinal muscular atrophy type 1 Journal of Neurology, Neurosurgery, and Psychiatry. 90 |
| Szabo S, Merikle E, Lozano-Ortega G, et al. (2018) Assessing the Relationship between Performance on the University of California Performance Skills Assessment (UPSA) and Outcomes in Schizophrenia: A Systematic Review and Evidence Synthesis. Schizophrenia Research and Treatment. 2018: 9075174 |
| Macek TA, McCue M, Dong X, et al. (2018) A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophrenia Research |
| Goldsmith P, Affinito J, McCue M, et al. (2017) A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events. Drugs in R&D |